ELVN-001 Shows Promising Efficacy Across Phase 1b CML Cohorts—69% Achieve Major Molecular Response in Challenging Patient Population

Efficacy and Safety Profile Stands Out in Heavily Pretreated Chronic Myeloid Leukemia (CML) Group

In a notable release today, Enliven Therapeutics shared positive initial results from its ongoing Phase 1b ENABLE clinical trial evaluating ELVN-001 in chronic myeloid leukemia (CML) patients who were relapsed, refractory, or intolerant to other tyrosine kinase inhibitors (TKIs). The data, current as of December 22, 2025, highlighted the compound’s strong efficacy profile, even among patients who have already received extensive prior treatment.

Across all evaluable patients in randomized cohorts, ELVN-001 delivered a cumulative major molecular response (MMR) rate of 69% by 24 weeks, and 53% of patients achieved MMR within that window. Deep molecular responses (DMR) were also recorded in 35% of patients. Importantly, the safety data remained consistent with earlier results—no new safety signals were observed, and all patients maintaining MMR at enrollment kept or improved their response.

Key Clinical Metrics: 24-Week Efficacy Data

Participants in these cohorts had been heavily pretreated: 53% had received four or more unique prior TKIs, and more than two-thirds had received asciminib, a recently approved agent, further emphasizing the high bar for meaningful clinical response. Despite the complex treatment history, ELVN-001’s efficacy compared favorably to precedent datasets from other available BCR::ABL1 TKIs.

Safety Remains Consistent Across Dose Levels—No New Concerns Identified

Safety and tolerability continue to stand out for ELVN-001. The trial reported no new safety signals, no maximum tolerated dose across the studied range (60 mg to 120 mg QD), and a profile that aligns well with prior findings. This is significant in a relapsed/refractory CML population, where side-effect management and durability of response can be particularly challenging.

Looking Ahead: 2026 Milestones Set to Shape ELVN-001’s Path

Enliven plans several significant milestones in 2026: mid-year presentation of further Phase 1 data from the ENABLE trial, regulatory FDA discussions focused on dose selection, and the launch of the pivotal Phase 3 ENABLE-2 trial in the second half of the year. Given the promising safety and efficacy to date, these next steps could position ELVN-001 as a best-in-class option for CML patients who have exhausted earlier therapies.

Takeaway: Strength in Efficacy, Stability in Safety—Key Signals for ELVN

ELVN-001’s latest Phase 1b data points toward a strong clinical profile, even among heavily pretreated patients—an essential market segment with few options. With a 69% cumulative MMR and durable responses coupled with a stable safety record, the stage is set for pivotal progress in 2026. Investors and clinicians alike may find these results worth a closer look as Enliven prepares for the next phase in this developing story.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI